Aarti Drugs Limited
NSE: AARTIDRUGS BSE: AARTIDRUGS
NSE
462.15
-1.10 (-0.24%)
Prev Close
463.25
Open Price
468.95
Volume
112,178
Today Low / High
460.85 / 469.7
52 WK Low / High
312 / 635
Range
439 - 485
BSE
462.05
-1.30 (-0.28%)
Prev Close
463.35
Open Price
467
Volume
17,719
Today Low / High
460.7 / 468.15
52 WK Low / High
312.5 / 632.1
Range
439 - 485
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 462.15 (target range: 439 - 485), reflecting a change of -1.1 (-0.23745%). On the BSE, it is listed at 462.05 (target range: 439 - 485), showing a change of -1.3 (-0.28057%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
06 Jun
468.95
-1.45%
05 Jun
479.00
-3.29%
04 Jun
468.00
1.21%
03 Jun
480.00
-3.33%
02 Jun
446.40
5.05%
30 May
472.80
-6.12%
29 May
474.00
-0.19%
28 May
474.80
-0.65%
27 May
470.00
0.02%
26 May
474.20
-1.47%
23 May
478.90
-0.98%
22 May
476.10
-0.29%
21 May
466.65
1.53%
20 May
484.50
-3.21%
19 May
462.80
3.85%
16 May
460.25
-1.15%
15 May
460.00
0.26%
14 May
453.50
1.97%
13 May
428.00
5.96%
12 May
429.05
-0.15%
09 May
409.00
2.36%
Aarti Drugs Limited Graph
Aarti Drugs Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Aarti Drugs Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 462.15, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 462.05 | 466.67 | 420.00 - 513.34 |
| 471.29 | 377.03 - 565.55 | ||
| 475.91 | 333.14 - 618.68 | ||
| Bearish Scenario | 462.05 | 457.43 | 411.69 - 503.17 |
| 452.81 | 362.25 - 543.37 | ||
| 448.19 | 313.73 - 582.65 |
Overview of Aarti Drugs Limited
ISIN
INE767A01016
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
476,169
Market Cap
42,180,430,500
Last Dividend
1
Official Website
IPO Date
2003-09-19
DCF Diff
49.34
DCF
413
Financial Ratios Every Investor Needs
Stock Dividend of AARTIDRUGS
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-02-04 | February 04, 25 | 1 | 1 | 2025-02-04 | 2025-02-28 | |
| 2024-02-06 | February 06, 24 | 1 | 1 | 2024-02-06 | 2024-02-23 | |
| 2023-02-08 | February 08, 23 | 1 | 1 | 2023-02-08 | 2023-02-26 | |
| 2022-02-09 | February 09, 22 | 1 | 1 | 2022-02-10 | 2022-03-02 | |
| 2020-11-03 | November 03, 20 | 2.5 | 2.5 | 2020-11-04 | 2020-11-22 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 2,508.87 Cr | 2,157.71 Cr | 351.17 Cr | 0.1400 | 0.00 Cr | 14.18 Cr | 277.70 Cr | 171.42 Cr | 18.56 | 320.49 Cr | 0.0683 |
| 2023-03-31 | 2,716.05 Cr | 1,888.51 Cr | 827.54 Cr | 0.3047 | 7.75 Cr | 13.37 Cr | 256.77 Cr | 166.31 Cr | 17.96 | 311.64 Cr | 0.0612 |
| 2022-03-31 | 2,488.65 Cr | 1,984.82 Cr | 503.83 Cr | 0.2024 | 6.61 Cr | 13.23 Cr | 288.39 Cr | 205.04 Cr | 22.14 | 343.91 Cr | 0.0824 |
| 2021-03-31 | 2,154.78 Cr | 1,554.47 Cr | 600.31 Cr | 0.2786 | 8.60 Cr | 9.44 Cr | 388.13 Cr | 280.41 Cr | 30.09 | 445.13 Cr | 0.1301 |
| 2020-03-31 | 1,806.09 Cr | 1,401.83 Cr | 404.26 Cr | 0.2238 | 8.74 Cr | 8.08 Cr | 213.42 Cr | 141.40 Cr | 15.17 | 271.47 Cr | 0.0783 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 6.74 Cr | 2,432.36 Cr | 1,150.40 Cr | 1,281.5485 Cr | 564.28 Cr | 557.54 Cr | 485.89 Cr | 1,053.94 Cr | 0.00 Cr | 0.00 Cr | 19.97 Cr | 795.5427 Cr |
| 2023-03-31 | 8.96 Cr | 2,421.40 Cr | 1,228.74 Cr | 1,192.4300 Cr | 608.91 Cr | 599.95 Cr | 516.29 Cr | 885.79 Cr | 4.37 Cr | 0.17 Cr | 18.80 Cr | 932.9800 Cr |
| 2022-03-31 | 21.61 Cr | 2,207.96 Cr | 1,171.66 Cr | 1,036.3611 Cr | 542.82 Cr | 521.20 Cr | 525.94 Cr | 766.52 Cr | 112.45 Cr | 0.17 Cr | 19.48 Cr | 940.0581 Cr |
| 2021-03-31 | 8.81 Cr | 1,766.01 Cr | 852.61 Cr | 913.4246 Cr | 350.76 Cr | 341.95 Cr | 415.00 Cr | 684.40 Cr | -39.61 Cr | 0.17 Cr | 17.30 Cr | 595.3559 Cr |
| 2020-03-31 | 6.77 Cr | 1,576.50 Cr | 924.01 Cr | 652.4894 Cr | 388.64 Cr | 381.87 Cr | 325.40 Cr | 654.53 Cr | 92.70 Cr | 0.17 Cr | 13.36 Cr | 624.7006 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 358.9232 Cr | -223.6508 Cr | -136.0331 Cr | 132.5887 Cr | -0.7607 Cr | 6.7427 Cr | -226.3345 Cr | 171.4182 Cr | -22.2845 Cr | -9.2673 Cr | 34.2458 Cr |
| 2023-03-31 | 134.2000 Cr | -163.9700 Cr | 16.5400 Cr | -30.4700 Cr | -13.2300 Cr | 8.3800 Cr | -164.6700 Cr | 224.1800 Cr | 61.3741 Cr | -9.4013 Cr | 5.8200 Cr |
| 2022-03-31 | 69.6357 Cr | -148.8616 Cr | 92.0251 Cr | -82.3392 Cr | 12.7991 Cr | 21.6120 Cr | -151.9749 Cr | 269.9551 Cr | 195.9490 Cr | -9.5077 Cr | -110.6302 Cr |
| 2021-03-31 | 154.8497 Cr | -71.6790 Cr | -81.1290 Cr | 66.7189 Cr | 2.0417 Cr | 8.8130 Cr | -88.1308 Cr | 369.0139 Cr | -34.9667 Cr | -23.2052 Cr | -89.1849 Cr |
| 2020-03-31 | 250.7438 Cr | -33.2093 Cr | -215.4067 Cr | 202.7532 Cr | 2.1278 Cr | 6.7713 Cr | -47.9906 Cr | 185.2885 Cr | -147.8249 Cr | -8.4668 Cr | -78.6888 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 556.60 Cr | 351.39 Cr | 205.21 Cr | 0.3687 | 47.93 Cr | 37.05 Cr | 4.06 | 73.63 Cr | 0.0666 |
| 2024-09-30 | 598.33 Cr | 434.28 Cr | 164.05 Cr | 0.2742 | 53.32 Cr | 35.01 Cr | 3.83 | 68.53 Cr | 0.0585 |
| 2024-06-30 | 555.34 Cr | 399.63 Cr | 155.71 Cr | 0.2804 | 51.57 Cr | 33.24 Cr | 3.62 | 66.06 Cr | 0.0599 |
| 2024-03-31 | 619.99 Cr | 436.55 Cr | 183.44 Cr | 0.2959 | 72.23 Cr | 47.31 Cr | 5.15 | 86.89 Cr | 0.0763 |
| 2023-12-31 | 605.94 Cr | 405.24 Cr | 200.70 Cr | 0.3312 | 59.15 Cr | 36.67 Cr | 3.99 | 71.80 Cr | 0.0605 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 11.34 Cr | 18.22 Cr | 29.56 Cr | 682.81 Cr | 470.00 Cr | 1,255.88 Cr | 1,134.06 Cr | 2,429.55 Cr | 1,151.76 Cr |
| 2024-06-30 | -20.77 Cr | 41.54 Cr | 20.77 Cr | 0.00 Cr | 0.00 Cr | 20.77 Cr | 0.00 Cr | 0.00 Cr | -1,281.97 Cr |
| 2024-03-31 | 9.43 Cr | 14.03 Cr | 9.43 Cr | 709.51 Cr | 485.89 Cr | 1,320.72 Cr | 1,035.14 Cr | 2,432.36 Cr | 1,150.40 Cr |
| 2023-12-31 | -24.99 Cr | 49.98 Cr | 24.99 Cr | 0.00 Cr | 0.00 Cr | 24.99 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 12.72 Cr | 12.27 Cr | 24.99 Cr | 703.57 Cr | 515.23 Cr | 1,338.10 Cr | 972.91 Cr | 2,351.83 Cr | 1,142.03 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | 33.24 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 47.37 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 36.67 Cr | 25.32 Cr | 0.00 Cr | 0.00 Cr | 25.32 Cr | 38.04 Cr | 12.72 Cr | 0.00 Cr | 25.32 Cr |
| 2023-09-30 | 39.59 Cr | 25.22 Cr | 0.00 Cr | 0.00 Cr | 25.22 Cr | 12.72 Cr | -12.50 Cr | 0.00 Cr | 25.22 Cr |
| 2023-06-30 | 47.85 Cr | 25.20 Cr | 0.00 Cr | 0.00 Cr | 25.20 Cr | 34.16 Cr | 8.96 Cr | 0.00 Cr | 25.20 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2020-09-30 | September 30, 20 | 4:1 |
| 2015-03-24 | March 24, 15 | 2:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,679.20 | ₹4,028,870,976,000.00 | ₹2,500,031.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,544.50 | ₹1,737,361,870,500.00 | ₹361,018.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,320.90 | ₹1,100,458,988,118.00 | ₹2,158,463.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,154.30 | ₹1,067,557,063,500.00 | ₹86,576.00 |
| Mankind Pharma Limited | MANKIND | ₹2,352.40 | ₹970,767,378,020.00 | ₹353,197.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹960.15 | ₹966,131,734,500.00 | ₹810,089.00 |
| Lupin Limited | LUPIN | ₹1,999.60 | ₹913,207,322,000.00 | ₹1,289,535.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,161.10 | ₹674,369,202,200.00 | ₹392,642.00 |
| Alkem Laboratories Limited | ALKEM | ₹4,862.50 | ₹581,384,812,500.00 | ₹181,782.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,590.20 | ₹448,756,030,200.00 | ₹940,265.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Cohance Lifesciences Limited | COHANCE | ₹1,055.10 | ₹403,646,450,141.00 | ₹209,681.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,370.90 | ₹347,802,813,600.00 | ₹594,702.00 |
| Laurus Labs Limited | LAURUSLABS | ₹642.05 | ₹346,227,388,650.00 | ₹1,658,718.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,571.30 | ₹321,186,225,600.00 | ₹84,218.00 |
| Piramal Enterprises Limited | PEL | ₹1,173.70 | ₹266,051,968,600.00 | ₹1,087,297.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,702.30 | ₹265,322,180,300.00 | ₹62,791.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,790.00 | ₹244,750,000,000.00 | ₹123,199.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,505.40 | ₹244,595,886,600.00 | ₹803,276.00 |
| Eris Lifesciences Limited | ERIS | ₹1,638.30 | ₹223,111,885,500.00 | ₹55,563.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹987.60 | ₹194,125,618,800.00 | ₹40,498.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,140.00 | ₹181,580,340,000.00 | ₹116,733.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,030.00 | ₹167,173,597,000.00 | ₹539,376.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,093.30 | ₹159,115,291,610.00 | ₹64,315.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹858.30 | ₹153,730,113,000.00 | ₹354,578.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹529.95 | ₹128,536,192,800.00 | ₹485,798.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,560.50 | ₹92,300,963,700.00 | ₹8,096.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹914.45 | ₹89,424,888,505.00 | ₹310,698.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹909.25 | ₹82,409,528,235.00 | ₹242,116.00 |
| Strides Pharma Science Limited | STAR | ₹782.30 | ₹72,098,880,210.00 | ₹430,298.00 |
| FDC Limited | FDC | ₹429.20 | ₹69,878,052,000.00 | ₹308,089.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹165.55 | ₹53,724,617,100.00 | ₹2,347,837.00 |
| Innova Captab Limited | INNOVACAP | ₹889.10 | ₹50,878,685,263.00 | ₹72,505.00 |
| Suven Life Sciences Limited | SUVEN | ₹221.19 | ₹48,235,788,060.00 | ₹1,475,325.00 |
| Sequent Scientific Limited | SEQUENT | ₹187.85 | ₹47,019,230,700.00 | ₹442,806.00 |
| Hikal Limited | HIKAL | ₹372.35 | ₹45,911,127,350.00 | ₹154,610.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹462.15 | ₹42,180,430,500.00 | ₹112,178.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹592.90 | ₹41,743,598,820.00 | ₹18,878.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹368.10 | ₹36,912,331,800.00 | ₹50,918.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹718.15 | ₹36,423,921,665.00 | ₹149,821.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,141.70 | ₹35,421,576,300.00 | ₹12,390.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹64.12 | ₹35,134,810,480.00 | ₹2,840,731.00 |
| Alembic Limited | ALEMBICLTD | ₹112.07 | ₹28,777,558,628.00 | ₹591,652.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹88.74 | ₹26,047,585,980.00 | ₹1,118,303.00 |
| Indoco Remedies Limited | INDOCO | ₹275.10 | ₹25,377,397,290.00 | ₹25,198.00 |
Key Executives
Chairman, MD, Chief Executive Officer & Head of BR
Mr. Prakash Moreshwar Patil
Gender: male
Year Born: 1947
Joint MD & Executive Director
Mr. Harshit Manila Savla
Gender: male
Year Born: 1962
Chief Financial Officer & Chief Operating Officer
Mr. Adhish Prakash Patil
Gender: male
Year Born: 1983
Whole-Time Director
Mr. Uday Moreshwar Patil
Gender: male
Year Born: 1963
Whole-Time Director
Mr. Harit Pragji Shah
Gender: male
Year Born: 1963
Managing Director of the Pinnacle Life Science Private Limited
Mr. Vishwa Harshit Savla
Gender: male
Year Born:
MD & Executive Director
Mr. Rashesh Chandrakant Gogri
Gender: male
Year Born: 1974
Company Secretary & Compliance Officer
Mr. Rushikesh Vivek Deole
Gender: male
Year Born:
Vice President of Technical
Mr. Dhanaji L. Kakade
Gender: male
Year Born:
FAQs about Aarti Drugs Limited
Who is the CEO of the company?
The CEO is Mr. Prakash Moreshwar Patil.
What is the current market price of the stock?
The current price is ₹462.15.
What is the 52-week price range?
The range is ₹312-635.
What is the market capitalization of the company?
The market capitalization is ₹4,218.04 crores.
What is the dividend yield?
The dividend yield is 0.22%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 27.64.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Aarti Drugs Limited (ISIN: INE767A01016) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹4,218.04 crores and an average daily volume of 476,169 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹1.